Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is June 4, 2025, covering a share repurchase executed on June 3, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full-period financial results. Key metrics for the June 3, 2025 transaction include:
- Shares Purchased: 417,924 ordinary shares.
- Price Range: Lowest price paid was 1,476.50 GBp; highest price paid was 1,518.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 1,495.25 GBp.
- Trading Venue: All trades occurred on the London Stock Exchange (XLON).
Since the commencement of the programme on February 24, 2025, GSK has purchased an aggregate of 49,064,080 ordinary shares. Following this transaction, the company holds 218,134,383 ordinary shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,097,132,891.
Material Changes and Capital Structure
The purchase of 417,924 shares represents a routine execution of the ongoing buyback programme. The filing confirms that the percentage of voting rights attributable to ordinary shares held in treasury is now 5.32%. The total number of voting rights in the company remains 4,097,132,891. No other material changes to the company's financial position, debt, or liquidity are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing does not contain new financial guidance, management commentary on operational performance, or specific risk factors beyond a standard cautionary statement. The company notes that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025. The purchased shares will be held as Treasury shares.
Important Facts for Investor Verification
- Verify the total remaining authorization under the buyback programme announced on February 24, 2025, to assess future repurchase capacity.
- Confirm the impact of the 5.32% treasury share holding on earnings per share (EPS) calculations in upcoming financial reports.
- Review the Q1 2025 results and 2024 Form 20-F for the full context of the company's liquidity and debt profile, as this filing only covers share transaction data.
- Note that the VWAP of 1,495.25 GBp reflects the market price during the trading session on June 3, 2025.